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Background: Testicular Germ Cell Tumours (TGCT) are the most frequently occurring malignancy in males from
15–45 years of age. They are derived from germ cells unable to undergo physiological maturation, although the
genetic basis for this is poorly understood. A recent report showed that mutations in the RNase IIIb domain of
DICER1, a micro-RNA (miRNA) processing enzyme, are common in non-epithelial ovarian cancers. DICER1 mutations
were found in 60% of Sertoli-Leydig cell tumours, clustering in four codons encoding metal-binding sites.
Additional analysis of 14 TGCT DNA samples identified one case that also contained a mutation at one of these
sites.
Findings: A number of previous studies have shown that DICER1 mutations are found in <1% of most cancers. To
provide a more accurate estimate of the frequency of such mutations in TGCTs, we have analysed 96 TGCT samples
using high resolution melting curve analysis for sequence variants in these four codons. Although we did not
detect any mutations in any of these sites, we did identify a novel mutation (c.1725 R>Q) within the RNase IIIb
domain in one TGCT sample, which was predicted to disturb DICER1 function.
Conclusion: Overall our findings suggest a mutation frequency in TGCTs of ~1%. We conclude therefore that
hot-spot mutations, frequently seen in Sertoli-Leydig cell tumours, are not common in TGCTs.
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Background
Testicular germ cell tumours (TGCTs), also referred to
as type II TGCTs, are the most common cancer affect-
ing adolescent and young men, and are typically diag-
nosed around the age of 30. TGCTs are classified based
on a number of features, including clinical characteris-
tics and histological markers [1]. TGCTs are derived
from immature germ cells that did not mature during
embryonic development [2,3], and can be subdivided
into seminomas and non-seminomas. Seminomas con-
sist of transformed germ cells that do not exhibit overt
pluripotency, although expressing SOX17, OCT3/4 and
NANOG [4,5]. In contrast, non-seminomas are trans-
formed germ cells that have reactivated pluripotency, as
evidenced by the expression of SOX2, OCT3/4 and
NANOG [6], three main regulators of pluripotency.* Correspondence: stefan.white@monash.edu
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reproduction in any medium, provided the orMicro-RNAs (miRNAs) play key roles in regulating
mRNA levels [7]. All miRNAs are derived from precur-
sor sequences, which are processed by DICER1 to form
double stranded RNA duplexes. These duplexes consist
of a principle miRNA strand and the (imperfectly) com-
plementary miRNA strand, referred to as miRNA* [8].
Germline mutations in DICER1 have been identified
in patients with pleuropulmonary blastoma [9], often
associated with goiter and Sertoli-Leydig cell tumours.
A recent report described the identification of recurrent,
somatic mutations in the DICER1 gene in nonepithelial
ovarian cancers [10]. The highest frequency of DICER1
mutations were found in Sertoli-Leydig cell tumours,
where 26 of 43 (60%) contained a somatic variant within
one of four hot-spot codons. All four codons encode for
acidic amino acids acting as metal binding sites within
the RNase IIIb domain of DICER1. Mutations affecting
any of these residues resulted in reduced RNase IIIb
activity.
Additional analysis of other tumour types identified a
somatic DICER1 hotspot mutation in one of 14 TGCTl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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domain of DICER1 also playing a role in TGCT develop-
ment. To better estimate the frequency of somatic var-
iants within these regions in TGCTs, we have analysed
96 TGCT samples using High Resolution Melting Curve
analysis, a powerful method widely used for identifying
variants in genomic DNA [11,12].Results
We have used HRM analysis to screen 96 TGCT sam-
ples for sequence variants in the four mutation hot-
spots codons identified in the RNase IIIb domain of
DICER1. To first demonstrate that HRM was able to de-
tect the specific variants previously identified in DICER1,
we created six different DNA templates (Table 1), each
containing one of the DICER1 mutations described in
[10] that was identified in more than one sample. Com-
bined, these six mutations cover 79% (26/33) of all cases
where a mutation within one of the hot-spot codons was
identified. For each variant, a heterozygous mutation
was simulated by combining the variant template with
an equimolar amount of a DNA template containing the
reference sequence. As shown in Figure 1, all six variants
could clearly be identified using HRM analysis.
We then used PCR primers (Table 2) to amplify the
corresponding genomic regions in 96 TGCT samples
to screen for these six variants. No samples showed an
aberrant melting curve.Table 1 DNA constructs created to simulate DICER1 hot-spot
Variant* Oligonucleotide se
1705_1709
Reference sequence 50-GGTGCTTGGTTATG
30-CCACGAACCAATA
c.5113G>A p.E1705K 50-GGTGCTTGGTTATG
30-CCACGAACCAATA
c.5125G>A p.D1709N 50-GGTGCTTGGTTATG
30-CCACGAACCAATA
c.5126A>G p.D1709G 50-GGTGCTTGGTTATG
30-CCACGAACCAATA
c.5127T>A p.D1709E 50-GGTGCTTGGTTATG
30-CCACGAACCAATA
1810_1813
Reference sequence 50-CATGTAAATGGCA
30-GTACATTTACCGTG
c.5428G>T p.D1810Y 50-CATGTAAATGGCA
30-GTACATTTACCGTG
c.5437G>C p.E1813Q 50-CATGTAAATGGCA
30-GTACATTTACCGTG
* Nucleotide and amino acid numbering are based on DICER1 reference sequence [
^ Priming sequences for PCR amplification (using primers listed in Table 2) are in caAs this initial analysis only covered a small amount of
genomic sequence (70 bp and 68 bp for the 1705/1709
and 1810/1813 codons respectively), we rescreened the
same 96 TGCT samples using primers described in [10]
(Table 2). These reactions generated products of 188 bp
and 194 bp, covering more of the RNase IIIb domain. In
these expanded assays, only one sample (a seminoma)
showed an aberrant curve with either primer pair
(Figure 2A). Sanger sequencing revealed a G>A transi-
tion (Figure 2B), predicted to change an Arginine to a
Glutamine at position 1725 (Figure 2C). This variant is
not listed in the 1000 Genome Project data [13], nor is it
present in Catalogue of Somatic Mutations in Cancer
(COSMIC), a database that curates mutations from a
range of different cancers [14].
Although the affected amino acid is not acidic, and
not predicted to directly function as a metal-binding site,
it is within a contiguous sequence of 37 amino acids that
show 100% conservation across at least 42 species. This
supports the hypothesis that this region within the
RNase IIIb domain is critical for normal DICER1 func-
tion. Indeed, analysis using PolyPhen2 [15] predicts the
impact of this variant to be “probably damaging” (score
1.0, sensitivity 0.0, specificity 1.0).Discussion
Somatic sequence variants are rare in TGCTs. Analysis
of 518 kinase genes in seven seminoma and six non-mutations
quences^
AGGTAGTCCaaaatcgcatctcccaggaattctaagCGCTGGTAACAATCTGAGGG-30
CTCCATCAGGttttagcgtagagggtccttaagattgGCGACCATTGTTAGACTCCC-50
AGGTAGTCCaaaatcgcatctcccaggaattTtaagCGCTGGTAACAATCTGAGGG-30
CTCCATCAGGttttagcgtagagggtccttaaAattgGCGACCATTGTTAGACTCCC-50
AGGTAGTCCaaaatcgcatTtcccaggaattctaagCGCTGGTAACAATCTGAGGG-30
CTCCATCAGGttttagcgtaAagggtccttaagattgGCGACCATTGTTAGACTCCC-50
AGGTAGTCCaaaatcgcaCctcccaggaattctaagCGCTGGTAACAATCTGAGGG-30
CTCCATCAGGttttagcgtGgagggtccttaagattgGCGACCATTGTTAGACTCCC-50
AGGTAGTCCaaaatcgcTtctcccaggaattctaagCGCTGGTAACAATCTGAGGG-30
CTCCATCAGGttttagcgAagagggtccttaagattgGCGACCATTGTTAGACTCCC-50
CCAGCAAgcgactcaaaaatatcccccatggCCTTTGGAACTTCAATATCCTCTT-30
GTCGTTcgctgagtttttatagggggtaccGGAAACCTTGAAGTTATAGGAGAA-50
CCAGCAAgcgactcaaaaatatAccccatggCCTTTGGAACTTCAATATCCTCTT-30
GTCGTTcgctgagtttttataTggggtaccGGAAACCTTGAAGTTATAGGAGAA-50
CCAGCAAgcgactGaaaaatatcccccatggCCTTTGGAACTTCAATATCCTCTT-30
GTCGTTcgctgaCtttttatagggggtaccGGAAACCTTGAAGTTATAGGAGAA-50
GenBank:NM_177438].
pital letters. The nucleotides representing the mutations are in bold.
Table 2 PCR amplification primers used in this study
Genomic region covered* Forward primer (50-30) Reverse primer (50-30) Product size Comment^
chr14:95560431-95560500 GGTGCTTGGTTATGAGGTAGTCC CCCTCAGATTGTTACCAGCG 70 bp Product includes codons
1705–1709 of DICER1; primer
sequences from this study
chr14:95557604-95557671 CATGTAAATGGCACCAGCAA AAGAGGATATTGAAGTTCCAAAGG 68 bp Product includes codons
1810–1813 of DICER1; primer
sequences from this study
chr14:95560345-95560533 CTTCTGCACAAGCTTACGGTTCCA CAGCGATGCAAAGATGGTGTTGT 188 bp Product includes codons
1705–1709 of DICER1; primer
sequences from [10].
chr14:95557565-95557759 TGGACTGCCTGTAAAAGTGG ACACACCTGCCAGACTGTCTCC 194 bp Product includes codons
1810–1813 of DICER1; primer
sequences from [10].
* Genomic location is based on reference sequence hg19.
^ Amino acid numbering is based on DICER1 reference sequence [GenBank:NM_177438].
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mutation, with an estimated mutation frequency of 0.12
per Mb [16]. A small number of genes are recurrently
mutated in TGCT, including KIT, KRAS2 and BRAF
[17,18], but in each case these represent <10% of
tumours analysed.#1
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Figure 2 A novel mutation identified within the DICER1 RNase IIIb domain in a single seminoma sample. Amino acid numbering is based
on DICER1 reference sequence [GenBank:NM_177438]. 2A. The aberrant HRM curve corresponding to the DICER1 mutation. The curves on the
baseline represent samples without a sequence variant (this was confirmed with Sanger sequencing in one sample). 2B. A Sanger sequencing
trace from the sample that showed the aberrant HRM curve in 2A. The heterozygous sequence variant is indicated by an arrow. This mutation is
predicted to change an Arginine to a Glutamine at position 1725 of DICER1. 2C. The RNase IIIb domain in DICER1, containing amino acids
1666–1824. The location of the mutation (R1725Q) identified in this study is shown by the red bar. The locations of the four metal-binding
residues (all acidic amino acids) frequently mutated in Sertoli-Leydig cell tumours are shown by black bars. The region of 100% conservation
across at least 42 species at the amino acid level (residues 1705–1741) is indicated by the horizontal black bar.
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gonadal ridge prior to sex determination. In contrast,
seminomas and non-seminomas are derived from germ
cells that have not undergone appropriate maturation.
As such, these two tumour types represent distinct cell
lineages.
The mutations in the RNaseIIIb domain were shown
to alter rather than abolish DICER1 activity, and it was
proposed that a specific miRNA expression profile
would be derived as a result of changes in RNase IIIb
activity [10]. The RNase IIIb domain is known to cut the
miRNA strand, with the miRNA* strand being cut by
the RNase IIIa domain [20]. Impaired RNase IIIb activitywould therefore be expected to result in a relative
increase in miRNA* production.
Several studies have shown increased expression of
certain miRNAs in TGCTs, primarily the miR302 and
miR37-373 clusters [21,22]. Indeed, expression of these
miRNAs is a hallmark of these cancers. These miRNAs
are also upregulated in embryonic stem cells and other
pluripotent cell types [23], and their high expression
levels in TGCTs are thought to represent the pluripotent
cell type of origin rather than specific genetic mutations
affecting expression levels [24]. We have recently per-
formed copy number variation and sequence analysis of
these miRNA loci in a large cohort of TGCTs, and did
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for altering miRNA levels (unpublished observations,
de Boer et al.).
Conclusion
In conclusion, we show that previously described hot-
spot mutations within the RNase IIIb domain of DICER1
are not frequent in TGCTs. It is likely that the high rate
of recurrent mutations observed in Sertoli-Leydig cell
tumours is due to specific characteristics of this tumour
type.
Materials and methods
TGCT samples
All TGCT DNA samples were extracted at Erasmus
University Medical Center, Rotterdam, the Netherlands.
The 96 samples consisted of 32 primary seminomas and
64 primary non-seminomas. None had been treated by
either chemotherapy or irradiation. Use of tissue samples
for scientific reasons was approved by an institutional
review board (MEC 02.981 and CCR2041). Samples were
used according to the “Code for Proper Secondary Use
of Human Tissue in The Netherlands” as developed by
the Dutch Federation of Medical Scientific Societies
(FMWV) Version 2002, update 2011). Genomic DNA
was isolated from peripheral blood lymphocytes follow-
ing standard protocols.
This project was approved by the Monash University
Human Research Ethics Committee, #CF11/1841.
Mutation analysis
All oligonucleotides were ordered from Sigma-Aldrich
(Castle Hill, Australia). Double-stranded DNA sequences
containing either the reference sequence, or one of the
six most commonly identified variants in [10], were
generated by annealing two complementary single-
stranded oligonucleotides of the appropriate sequences
(Table 1).
Primers for PCR amplification are listed in Table 2.
Amplification reactions were performed in 10 μl reaction
volumes, consisting of HRM Master Mix (Idaho Tech-
nologies, USA), 5 μM each of forward and reverse pri-
mer, and either 25 ng genomic DNA (TGCT samples) or
1 fmol of variant DNA template.
PCR reactions were carried out under the following
conditions; an initial hold at 95°C for 2 min, followed by
45 cycles of 94°C for 30 sec and 58°C for 30 sec. PCR
products were analysed in a 96 well plate in the Light-
Scanner (Idaho Technologies, USA). The HRM settings
for the LightScanner were as follows; start temperature
of 70°C, end temperature at 96°C, with a hold
temperature at 67°C. HRM curves were normalized using
GeneMelt software supplied with the instrument, and
samples that showed an aberrant melting curve wereanalysed by Sanger sequencing at the Gandel Charitable
Trust Sequencing Centre at the Monash Health Transla-
tion Precinct, Melbourne, Australia. Sequence traces
were visually assessed using 4Peaks software (Mek&Tosj,
Amsterdam, the Netherlands).
Bioinformatic analysis
The predicted effect of missense mutations was deter-
mined using PolyPhen2 [15].
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